Christopher J. Webster

Prevalence and Diagnosis of Migraine in Patients Consulting Their Physician With a Complaint of Headache: Data From the Landmark Study

Context.—Headache experts have suggested that to improve the recognition of migraine, patients with a stable pattern of episodic, disabling headache and a normal physical exam should be considered to have migraine in the absence of contradictory evidence. The premise upon which this approach is based—that is, that episodic, recurrent primary headache in the clinic is usually migraine—has not been evaluated in prospective clinical studies.

Naratriptan is Effective and Well Tolerated in the Acute Treatment of Migraine. Results of a Double-Blind, Placebo-Controlled, Parallel-Group Study†

Objective.‐To evaluate the efficacy and tolerability of naratriptan, a novel 5‐HT1 agonist, in the acute treatment of migraine.

Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.

Objective.—To compare the efficacy and tolerability of sumatriptan nasal spray (NS) (5, 20 mg) versus placebo in the acute treatment of migraine in adolescent subjects.

Long‐Term Tolerability of Sumatriptan Nasal Spray in Adolescent Patients With Migraine

Objective.—This 1‐year, open‐label, multicenter study was designed to assess the long‐term tolerability and efficacy of sumatriptan nasal spray 20 mg in adolescent patients with migraine.

Efficacy and Tolerability of Subcutaneous Sumatriptan for Acute Migraine: A Comparison Between Ethnic Groups

Objective.—To evaluate efficacy and tolerability of subcutaneous sumatriptan 6 mg versus placebo for acute migraine between ethnic groups.

Time to onset of efficacy of the fast-disintegrating/rapid-release formulation of sumatriptan tablets in the acute treatment of migraine

Time to onset of efficacy of the fast-disintegrating/rapid-release formulation of sumatriptan tablets in the acute treatment of migraine Reto Agosti , Carl G. H. Dahlöf , Wim m. mulleners , martin W. Jones , Chris Webster e and Colleen Few e Headache Center Hirslanden Zürich, Zürich, Switzerland Gothenburg Migraine Clinic, Gothenburg, Sweden Department of Neurology, Atrium Medical Center, Heerlen, The Netherlands GlaxoSmithKline, Greenford, United Kingdom GlaxoSmithKline, Research Triangle Park, North Carolina, United States